TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

The prevalence of MS in Australia has been increasing at an accelerating rate in recent years, according to a report from MS Australia.

TD Cowen analyst Tara Bancroft initiated coverage of TG Therapeutics (TGTX) with a Buy rating and $50 price target The company’s Briumvi ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Multiple sclerosis (MS) is typically treated with medications that aim to calm flare-ups, manage symptoms, and slow disease progression. Infusion therapy is often used to deliver certain ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target ...

Increased production of cholesterol by stem cells in the brain contributes to neurological damage in multiple sclerosis, a ...

On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to ...

Ocrevus sales increased 11% to 1.69 billion Swiss francs, while Vabysmo surged 59%. On Wednesday, Roche Holdings AG RHHBY released its third-quarter sales report. Sales increased 9% year over year ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...